Breakout Ventures announces $114M Fund III focused on early-stage neurotech and brain health
Summary
Breakout Ventures announced its $114M Fund III dedicated to early-stage companies developing neurotechnology, brain health diagnostics, and cognitive wellness technologies. Fund III will make 20-25 seed and Series A investments across BCIs, neuromodulation, AI neurodiagnostics, and digital mental health tools. Breakout is one of the few VC funds exclusively focused on neurotech and brain health, giving them deep domain expertise that generalist funds lack.
Why it matters
A $114M dedicated neurotech seed and Series A fund provides institutional early-stage capital for the pre-clinical and early clinical companies that often struggle to raise from generalist VCs who don't understand the FDA pathway timelines. Breakout Fund III filling this gap will enable more early-stage neurotech companies to survive to Series B.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial